RHOEN-KLINIKUM AG (RHK.DE) Fundamental Analysis & Valuation
FRA:RHK • DE0007042301
Current stock price
12.3 EUR
0 (0%)
Last:
This RHK.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. RHK.DE Profitability Analysis
1.1 Basic Checks
- RHK had positive earnings in the past year.
- In the past year RHK had a positive cash flow from operations.
- In the past 5 years RHK has always been profitable.
- RHK had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- RHK has a Return On Assets of 1.89%. This is in the lower half of the industry: RHK underperforms 64.29% of its industry peers.
- RHK has a worse Return On Equity (2.61%) than 71.43% of its industry peers.
- With a Return On Invested Capital value of 2.24%, RHK is not doing good in the industry: 75.00% of the companies in the same industry are doing better.
- RHK had an Average Return On Invested Capital over the past 3 years of 2.41%. This is below the industry average of 6.23%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.89% | ||
| ROE | 2.61% | ||
| ROIC | 2.24% |
ROA(3y)2.14%
ROA(5y)1.92%
ROE(3y)3.02%
ROE(5y)2.69%
ROIC(3y)2.41%
ROIC(5y)2.18%
1.3 Margins
- With a Profit Margin value of 2.02%, RHK is not doing good in the industry: 60.71% of the companies in the same industry are doing better.
- In the last couple of years the Profit Margin of RHK has grown nicely.
- With a Operating Margin value of 2.40%, RHK is not doing good in the industry: 78.57% of the companies in the same industry are doing better.
- RHK's Operating Margin has improved in the last couple of years.
- RHK has a Gross Margin of 66.87%. This is in the better half of the industry: RHK outperforms 71.43% of its industry peers.
- RHK's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.4% | ||
| PM (TTM) | 2.02% | ||
| GM | 66.87% |
OM growth 3Y1.67%
OM growth 5Y10.96%
PM growth 3Y5.16%
PM growth 5Y80.11%
GM growth 3Y-1.1%
GM growth 5Y-0.61%
2. RHK.DE Health Analysis
2.1 Basic Checks
- RHK has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- The number of shares outstanding for RHK remains at a similar level compared to 1 year ago.
- RHK has about the same amout of shares outstanding than it did 5 years ago.
- Compared to 1 year ago, RHK has an improved debt to assets ratio.
2.2 Solvency
- RHK has an Altman-Z score of 3.25. This indicates that RHK is financially healthy and has little risk of bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 3.25, RHK belongs to the top of the industry, outperforming 85.71% of the companies in the same industry.
- RHK has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
- With an excellent Debt to Equity ratio value of 0.09, RHK belongs to the best of the industry, outperforming 92.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.25 |
ROIC/WACC0.33
WACC6.74%
2.3 Liquidity
- RHK has a Current Ratio of 2.60. This indicates that RHK is financially healthy and has no problem in meeting its short term obligations.
- RHK has a better Current ratio (2.60) than 96.43% of its industry peers.
- RHK has a Quick Ratio of 2.49. This indicates that RHK is financially healthy and has no problem in meeting its short term obligations.
- The Quick ratio of RHK (2.49) is better than 96.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.6 | ||
| Quick Ratio | 2.49 |
3. RHK.DE Growth Analysis
3.1 Past
- RHK shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -21.07%.
- The Earnings Per Share has been growing by 88.40% on average over the past years. This is a very strong growth
- The Revenue has been growing slightly by 6.84% in the past year.
- Measured over the past years, RHK shows a small growth in Revenue. The Revenue has been growing by 4.62% on average per year.
EPS 1Y (TTM)-21.07%
EPS 3Y11.09%
EPS 5Y88.4%
EPS Q2Q%-25.1%
Revenue 1Y (TTM)6.84%
Revenue growth 3Y5.64%
Revenue growth 5Y4.62%
Sales Q2Q%4.24%
3.2 Future
- RHK is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.44% yearly.
- RHK is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.72% yearly.
EPS Next Y17.01%
EPS Next 2Y14.65%
EPS Next 3Y13.68%
EPS Next 5Y13.44%
Revenue Next Year3.87%
Revenue Next 2Y6.19%
Revenue Next 3Y5.92%
Revenue Next 5Y5.72%
3.3 Evolution
- Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. RHK.DE Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 24.12, which indicates a rather expensive current valuation of RHK.
- 64.29% of the companies in the same industry are cheaper than RHK, based on the Price/Earnings ratio.
- The average S&P500 Price/Earnings ratio is at 27.50. RHK is around the same levels.
- Based on the Price/Forward Earnings ratio of 16.09, the valuation of RHK can be described as correct.
- The rest of the industry has a similar Price/Forward Earnings ratio as RHK.
- RHK is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.62, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.12 | ||
| Fwd PE | 16.09 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, RHK is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 0.3 |
4.3 Compensation for Growth
- RHK's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- RHK's earnings are expected to grow with 13.68% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.42
PEG (5Y)0.27
EPS Next 2Y14.65%
EPS Next 3Y13.68%
5. RHK.DE Dividend Analysis
5.1 Amount
- With a Yearly Dividend Yield of 1.63%, RHK has a reasonable but not impressive dividend return.
- RHK's Dividend Yield is comparable with the industry average which is at 1.84.
- Compared to an average S&P500 Dividend Yield of 1.81, RHK has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.63% |
5.2 History
- The dividend of RHK decreases each year by -19.15%.
Dividend Growth(5Y)-19.15%
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
- RHK pays out 19.44% of its income as dividend. This is a sustainable payout ratio.
DP19.44%
EPS Next 2Y14.65%
EPS Next 3Y13.68%
RHK.DE Fundamentals: All Metrics, Ratios and Statistics
FRA:RHK (4/22/2026, 7:00:00 PM)
12.3
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-26 2026-03-26
Earnings (Next)05-07 2026-05-07
Inst Owners0.53%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap823.61M
Revenue(TTM)1.70B
Net Income(TTM)34.47M
Analysts74.29
Price Target14.45 (17.48%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.63% |
Yearly Dividend0.1
Dividend Growth(5Y)-19.15%
DP19.44%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)-0.11%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.12 | ||
| Fwd PE | 16.09 | ||
| P/S | 0.48 | ||
| P/FCF | N/A | ||
| P/OCF | 14.4 | ||
| P/B | 0.62 | ||
| P/tB | 0.71 | ||
| EV/EBITDA | 0.3 |
EPS(TTM)0.51
EY4.15%
EPS(NY)0.76
Fwd EY6.21%
FCF(TTM)-0.63
FCFYN/A
OCF(TTM)0.85
OCFY6.95%
SpS25.46
BVpS19.72
TBVpS17.21
PEG (NY)1.42
PEG (5Y)0.27
Graham Number15.0438 (22.31%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.89% | ||
| ROE | 2.61% | ||
| ROCE | 2.77% | ||
| ROIC | 2.24% | ||
| ROICexc | 3.53% | ||
| ROICexgc | 4.31% | ||
| OM | 2.4% | ||
| PM (TTM) | 2.02% | ||
| GM | 66.87% | ||
| FCFM | N/A |
ROA(3y)2.14%
ROA(5y)1.92%
ROE(3y)3.02%
ROE(5y)2.69%
ROIC(3y)2.41%
ROIC(5y)2.18%
ROICexc(3y)3.18%
ROICexc(5y)2.84%
ROICexgc(3y)3.77%
ROICexgc(5y)3.38%
ROCE(3y)2.99%
ROCE(5y)2.71%
ROICexgc growth 3Y5.1%
ROICexgc growth 5Y14.06%
ROICexc growth 3Y5.79%
ROICexc growth 5Y14.64%
OM growth 3Y1.67%
OM growth 5Y10.96%
PM growth 3Y5.16%
PM growth 5Y80.11%
GM growth 3Y-1.1%
GM growth 5Y-0.61%
F-Score6
Asset Turnover0.94
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 1.12 | ||
| Cap/Depr | 152.7% | ||
| Cap/Sales | 5.81% | ||
| Interest Coverage | 13.22 | ||
| Cash Conversion | 54.02% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.6 | ||
| Quick Ratio | 2.49 | ||
| Altman-Z | 3.25 |
F-Score6
WACC6.74%
ROIC/WACC0.33
Cap/Depr(3y)120.3%
Cap/Depr(5y)111.07%
Cap/Sales(3y)4.84%
Cap/Sales(5y)4.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.07%
EPS 3Y11.09%
EPS 5Y88.4%
EPS Q2Q%-25.1%
EPS Next Y17.01%
EPS Next 2Y14.65%
EPS Next 3Y13.68%
EPS Next 5Y13.44%
Revenue 1Y (TTM)6.84%
Revenue growth 3Y5.64%
Revenue growth 5Y4.62%
Sales Q2Q%4.24%
Revenue Next Year3.87%
Revenue Next 2Y6.19%
Revenue Next 3Y5.92%
Revenue Next 5Y5.72%
EBIT growth 1Y-15.46%
EBIT growth 3Y7.4%
EBIT growth 5Y16.08%
EBIT Next Year147.39%
EBIT Next 3Y44.65%
EBIT Next 5Y34.3%
FCF growth 1Y-173.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-55.17%
OCF growth 3Y-1.74%
OCF growth 5Y-12.78%
RHOEN-KLINIKUM AG / RHK.DE Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for RHOEN-KLINIKUM AG?
ChartMill assigns a fundamental rating of 5 / 10 to RHK.DE.
What is the valuation status of RHOEN-KLINIKUM AG (RHK.DE) stock?
ChartMill assigns a valuation rating of 3 / 10 to RHOEN-KLINIKUM AG (RHK.DE). This can be considered as Overvalued.
How profitable is RHOEN-KLINIKUM AG (RHK.DE) stock?
RHOEN-KLINIKUM AG (RHK.DE) has a profitability rating of 4 / 10.
How financially healthy is RHOEN-KLINIKUM AG?
The financial health rating of RHOEN-KLINIKUM AG (RHK.DE) is 7 / 10.
What is the earnings growth outlook for RHOEN-KLINIKUM AG?
The Earnings per Share (EPS) of RHOEN-KLINIKUM AG (RHK.DE) is expected to grow by 17.01% in the next year.